MGNX Rises After Gilead Exercises Option on Bispecific Program
Gilead pays MacroGenics $10 million to license a TRIDENT-based bispecific for solid tumors, extending its cash runway to 2028.
/ 4 items
#MGNX↓
MacroGenics to Receive $24.5 Million Milestone Payment from Sanofi Following FDA Approval of TZIELD for Stage 3 Type 1 Diabetes
MacroGenics receives $24.5 million from Sanofi after FDA expands TZIELD approval to children aged 8-17 with newly diagnosed stage 3 Type 1 diabetes.
MacroGenics Sells GMP Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million
MacroGenics sells manufacturing site to Bora for $122.5M, keeps access, gains cash, and focuses on cancer drug development.
MacroGenics’ LINNET Trial Back on Track After FDA Removes Partial Hold
FDA lifted hold on MacroGenics’ cancer study. New patients can join again; drug helps immune system fight tough ovarian cancers.